GLP-1 Fat-Loss Stack
GLP-1 drug plus add-on metabolism peptides
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The combination itself is essentially unstudied. There is no published trial, controlled or otherwise, testing a GLP-1 receptor agonist plus AOD-9604, MOTS-c, or 5-Amino-1MQ against the GLP-1 alone. Every claim of added benefit is an inference stacked on top of separate and much weaker literatures. The GLP-1 core is genuinely strong evidence, with STEP, SURMOUNT, and SELECT giving large randomised data on weight, glycaemia, and cardiovascular outcomes. Beyond that the ground gives way. AOD-9604 was taken into human obesity trials and did not beat placebo on weight in its pivotal work, which is a rare instance of an add-on peptide actually being tested and failing. MOTS-c evidence is largely rodent and cell work on insulin sensitivity and exercise metabolism, with no meaningful human weight-loss data. 5-Amino-1MQ has been studied as an NNMT inhibitor in mice, where it reduced adiposity, and human trials are effectively absent. Nobody has tested whether these are additive, redundant, or interfering when layered onto an already potent appetite suppressant, and any observed result in a user is far more plausibly the GLP-1 doing its work.
- FDA
- The GLP-1 base drugs are FDA-approved: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are cleared for diabetes and/or obesity. GLP-1 means glucagon-like peptide-1, a gut hormone that signals fullness; tirzepatide also hits a second receptor called GIP. The add-on peptides are NOT approved as weight drugs: AOD-9604 has no drug approval (it holds a narrow food-ingredient GRAS notice and the FDA declined to add it to the compounding list in December 2024), and MOTS-c and 5-Amino-1MQ are sold as research chemicals only. The stack as a whole is not an approved regimen.
- WADA
- Allowed
Reference only. Not medical advice.
What can go wrong
PROMINENT RISK. GLP-1 drugs commonly cause nausea (around 44% in one semaglutide trial), vomiting, diarrhea, and constipation, and can cause significant loss of lean muscle (roughly a third of weight lost), which resistance training and adequate protein may reduce. Rarer GLP-1 concerns include pancreatitis, gallbladder problems, and reports under postmarketing review. The add-on peptides are the bigger unknown: AOD-9604, MOTS-c, and 5-Amino-1MQ lack human safety data for this use, and most are sold as gray-market or compounded research chemicals with no guarantee of purity, dose accuracy, or sterility. Injecting non-sterile or mislabeled product carries infection and contamination risk. Stacking multiple agents can compound side effects and makes it impossible to know which substance caused a problem.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about GLP-1 Fat-Loss Stack. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
This stack pairs a proven weight-loss drug with extra peptides that the community hopes will burn more fat or protect muscle. The core is a GLP-1 receptor agonist: semaglutide or tirzepatide, the active ingredients in Ozempic, Wegovy, Mounjaro, and Zepbound, which are FDA-approved and backed by large trials. These drugs work mainly by reducing appetite, and in SURMOUNT-1 tirzepatide produced average weight loss near 20.9% at 72 weeks versus about 3.1% on placebo. On top, clinics and users sometimes add AOD-9604 (a fat-cell fragment of growth hormone), MOTS-c (a mitochondrial peptide), or 5-Amino-1MQ (an oral enzyme blocker), claiming faster fat loss or better metabolism. None of those three add-ons is an approved weight-loss medicine, and their human evidence is thin to absent. AOD-9604 actually failed its main obesity trial in 2007, and MOTS-c and 5-Amino-1MQ have essentially no published human weight-loss trials. So the stack mixes one well-tested part with several parts whose benefit and safety in people are unknown.
approved drug plus unproven add-ons
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Safety in detail
The regulatory picture is split. Semaglutide and tirzepatide hold approvals in the United States, the European Union, the United Kingdom, Japan, Australia, and much of the world, though indications and reimbursement differ sharply by country. The add-ons hold no weight-loss approval anywhere. AOD-9604 sits in an odd niche with a narrow US food-ingredient status and is sold in Australia as a research chemical, while MOTS-c and 5-Amino-1MQ are sold almost entirely as unregulated research products. Grey-market vials carry real sourcing risk, since purity, dose accuracy, and sterility are unverified. What remains genuinely unknown is whether any of the three add-ons interacts with GLP-1 pharmacology at all, favourably or otherwise. No one has looked.
What people get wrong
Often saidMyth: The add-on peptides are what make the weight come off.
ActuallyReality: The FDA-approved GLP-1 drug does the proven work; AOD-9604 failed its 2007 obesity trial, and MOTS-c and 5-Amino-1MQ have essentially no human weight-loss data.
Often saidMyth: If a clinic bundles it, the whole stack is proven.
ActuallyReality: Only the GLP-1 core is FDA-approved; the add-ons are unapproved research chemicals, and you cannot tell which substance caused a side effect when several are combined.
Who profits, and who pushes back
Obesity-medicine physicians
The GLP-1 drug does the real work; the extra peptides add cost and unknown risk without proven benefit.
FDA and pharmacology reviewers
AOD-9604, MOTS-c, and 5-Amino-1MQ have no approved weight-loss indication and limited or no human efficacy data.
Academic researchers
AOD-9604 failed its 2007 phase 2b obesity endpoint; current stacking claims outrun the evidence.
Telehealth weight and wellness clinics
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Market GLP-1-plus-peptide bundles on subscription; direct financial stake in the add-ons.
Compounding pharmacies
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Produce compounded GLP-1 and peptide blends; revenue depends on continued demand.
Fitness and biohacking influencers
Mix of paid affiliates and genuine believers; often present add-ons as proven when they are not.
Eli Lilly and Novo Nordisk
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Profit from the approved GLP-1 core only; do not endorse the off-label add-on peptides.
Where the research comes from
Most of the published research on this comes from one place. 70% of it is from North America. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| North America | 70% |
| Europe | 15% |
| Asia-Pacific | 10% |
| Other | 5% |
Research published from: USA.
How we got here
Nothing about this stack carries a single inventor's name. The base drugs do. Semaglutide came out of Novo Nordisk's long effort to make a GLP-1 analogue that survived once-weekly dosing, and tirzepatide out of Eli Lilly's work on a molecule that engages both the GIP and GLP-1 receptors. AOD-9604 is the older and stranger component, a synthetic fragment corresponding to the C-terminal region of human growth hormone, developed at Monash University with Metabolic Pharmaceuticals in Australia and later licensed for non-drug uses after its obesity programme stalled. MOTS-c emerged from mitochondrial genomics research associated with Pinchas Cohen's group at the University of Southern California, described as a peptide encoded within mitochondrial DNA. 5-Amino-1MQ is not a peptide at all, but a small-molecule NNMT inhibitor that came from academic metabolic chemistry and drifted into the supplement grey market. The pairing of these with a GLP-1 appears to have been assembled by telehealth prescribers, compounding pharmacies, and peptide vendors during the GLP-1 boom of roughly 2022 onward, spreading through Reddit, bodybuilding forums, and clinic marketing rather than through any published protocol.
The validated core has a clear lineage: Novo Nordisk developed semaglutide and Eli Lilly developed tirzepatide, both with large published trials (STEP, SURMOUNT, SELECT). The practice of adding unproven peptides is not traceable to a single named originator; it spread through telehealth and wellness clinics roughly 2022-2024 as GLP-1 demand surged. AOD-9604 traces to Monash University and Metabolic Pharmaceuticals in the 1990s-2000s, where it failed as an obesity drug. The combined stack itself has uncertain origin and appears driven by commercial bundling rather than a documented scientific protocol.
- 2007AOD-9604 fails its phase 2b obesity trial; Metabolic Pharmaceuticals ends obesity development
- 2017Semaglutide (Ozempic) approved for type 2 diabetes
- 2021Semaglutide (Wegovy) approved for chronic weight management
- 2022Tirzepatide (Mounjaro) approved; SURMOUNT-1 weight data emerge
- 2023Tirzepatide (Zepbound) approved for obesity; GLP-1 demand surges
- 2024FDA declines to add AOD-9604 to the compounding list (December)
- 2026Add-on peptides MOTS-c and 5-Amino-1MQ remain research-only with no published human weight trials
At a glance
- Approved core
- Semaglutide and tirzepatide (FDA-cleared)
- Unproven add-ons
- AOD-9604, MOTS-c, 5-Amino-1MQ (research only)
- Tirzepatide weight loss
- Up to ~20.9% at 72 weeks (SURMOUNT-1)
- Lean mass caveat
- ~33-39% of weight lost can be lean mass
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about GLP-1 Fat-Loss Stack. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
Tirzepatide produced mean weight reduction near 20.9 percent at 72 weeks versus about 3.1 percent with placebo in adults with obesity.
New England Journal of Medicine (SURMOUNT-1, Jastreboff et al.)
Once-weekly semaglutide 2.4 mg produced roughly 15 percent mean body weight loss over 68 weeks in adults without diabetes, with gastrointestinal side effects common.
Semaglutide reduced major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease without diabetes.
Semaglutide and tirzepatide are approved prescription medicines for chronic weight management and type 2 diabetes, with specific labelled indications and warnings.
FDA has repeatedly warned about compounded and counterfeit GLP-1 products sold outside the regulated supply chain, including dosing errors and unverified ingredients.
AOD-9604 was investigated as an obesity drug and did not demonstrate significant weight loss over placebo in its principal human trial programme.
Peer-reviewed obesity pharmacology literature on AOD-9604 (Metabolic Pharmaceuticals programme)
MOTS-c is a mitochondrial-derived peptide characterised mainly in rodent and cell models for effects on insulin sensitivity and metabolic homeostasis, with no established human weight-loss evidence.
Cell Metabolism (Lee et al., original MOTS-c characterisation)
5-Amino-1MQ is a small-molecule nicotinamide N-methyltransferase inhibitor that reduced fat mass in diet-induced obese mice, without human efficacy trials.
Preclinical NNMT inhibitor literature
GLP-1 receptor agonists are not prohibited in sport, while unapproved peptides sold alongside them may fall under prohibited categories depending on the substance.